J&J's Janssen, Arrowhead Launch Up-to-$3.7B RNAi Partnership Including Hep B Candidate

Johnson & Johnson’s Janssen Pharmaceuticals will partner with Arrowhead Pharmaceuticals to develop an RNA interference (RNAi) treatment candidate for hepatitis B virus (HBV), plus up to three other RNAi therapies against targets to be selected by Janssen, through a collaboration Arrowhead said could generate for it more than $3.7 billion.The companies’ license and collaboration agreement gives Janssen a global exclusive license to Arrowhead’s ARO-HBV program, designed to de